RECBIO-B (02179): Xu Haoyu Elected as Chairman

Stock News2025-12-23

RECBIO-B (02179) announced that the company's board of directors received the resignation letter from Dr. Liu Yong on December 22, 2025. To further enhance corporate governance and allocate more time to other commitments, Dr. Liu Yong resigned from his positions as Chairman of the Board and Chairman of the Nomination Committee, effective from the date of the election of a new Chairman. Dr. Liu Yong will continue to serve as an Executive Director and General Manager, overseeing the company's production and operational management.

The board is pleased to announce that during a board meeting held on December 23, 2025, Mr. Xu Haoyu was elected as Chairman of the second-term board of directors. His tenure will commence upon approval by the board and continue until the end of the second-term board's tenure.

Following Dr. Liu Yong's resignation and in compliance with the Listing Rules, the Company Law of the People's Republic of China, the Corporate Governance Guidelines for Listed Companies, the Company's Articles of Association, and the Nomination Committee's working procedures, the board elected Professor GAO Feng as Chairman of the second-term Nomination Committee and Ms. Wang Jing as a member of the committee during the same meeting. Their terms will also take effect upon board approval and last until the conclusion of the second-term board's tenure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment